MCID: DCT002
MIFTS: 41

Ductal Carcinoma in Situ malady

Cancer category

Summaries for Ductal Carcinoma in Situ

Sources:
64Wikipedia, 33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
Wikipedia:64 Mammary ductal carcinoma is the most common type of breast cancer in women. It comes in two forms:... more...

MalaCards: Ductal Carcinoma in Situ is related to breast cancer, invasive ductal and papillary carcinoma. An important gene associated with Ductal Carcinoma in Situ is ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), and among its related pathways are Akt Signaling and GPCR Pathway. The compounds progesterone and paraffin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, pancreas and breast, and related mouse phenotypes are homeostasis/metabolism and tumorigenesis.

Aliases & Classifications for Ductal Carcinoma in Situ

Sources:
8Disease Ontology, 10DISEASES
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer


Aliases & Descriptions:

ductal carcinoma in situ 8 10


External Ids:

Disease Ontology8 DOID:0060074

Related Diseases for Ductal Carcinoma in Situ

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 97)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer, invasive ductal31.5CCND1, TFF1, PGR, KRT14, ERBB2
2papillary carcinoma30.8ERBB2, ACTC1, KRT14, PGR
3squamous cell carcinoma30.3TFF1, S100A7, CCND1, KLK10, PIP, CLDN7
4inflammatory breast carcinoma30.3ERBB2, PGR
5anal carcinoma in situ10.7
6invasive mole10.7
7gynecomastia10.6
8comedo carcinoma10.6
9intraductal papilloma10.6
10neuroendocrine carcinoma10.6
11flat ductal epithelial atypia10.6
12breast reconstruction10.5
13breast papillary carcinoma10.5
14lobular neoplasia10.5
15breast apocrine carcinoma10.5
16nipple duct carcinoma10.5
17hypoxia10.5
18cribriform carcinoma10.4
19myoepithelial carcinoma10.4
20anal margin carcinoma10.4
21bilateral breast cancer10.4
22prolactinoma10.2
23estrogen-receptor positive breast cancer10.2
24estrogen-receptor negative breast cancer10.2
25progesterone-receptor negative breast cancer10.2
26parathyroid carcinoma10.2
27breast adenomyoepithelioma10.2
28bone carcinoma10.2
29mccune albright syndrome10.2
30proteus syndrome10.2
31synchronous bilateral breast carcinoma10.2
32breast myoepithelial carcinoma10.2
33poland syndrome10.2
34pyoderma gangrenosum10.2
35vascular disease10.2
36mccune–albright syndrome10.2
37char syndrome10.2
38breast cancer, lobular10.2
39phyllode tumor10.2
40adenocarcinoma10.0PIP, TFF1, CCND1, TIMP4, BNIP3, CLDN7
41breast cancer10.0CCND1, TFF1, PIP, PGR, KRT14, MST1R
42lung cancer10.0SAGE1, TFF1, PIP, KRT5, KRT14, ERBB2
43colorectal cancer10.0BNIP3, CCND1, TFF1, KRT5, KRT14, ERBB2
44adenoid cystic carcinoma10.0CCND1, KRT14, ACTC1, ERBB2
45adenoma10.0ACTC1, KRT14, TFF1, CCND1
46papilloma10.0ACTC1, KRT14, KRT5
47malignant mixed mullerian tumor10.0ERBB2, ACTC1, PGR
48fibromatosis10.0TFF1, PGR, ACTC1
49tubular adenocarcinoma10.0ERBB2, ACTC1, PGR
50oral cancer10.0KRT14, KRT5, CCND1

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to ductal carcinoma in situ

Clinical Features for Ductal Carcinoma in Situ

Drugs & Therapeutics for Ductal Carcinoma in Situ

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials
See all sources

Approved drugs:

Search CenterWatch for Ductal Carcinoma in Situ

Drug clinical trials:

Search ClinicalTrials for Ductal Carcinoma in Situ

Search NIH Clinical Center for Ductal Carcinoma in Situ

Search CenterWatch for Ductal Carcinoma in Situ

Genetic Tests for Ductal Carcinoma in Situ

Anatomical Context for Ductal Carcinoma in Situ

Sources:
33MalaCards
See all sources

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

33
Lymph node, Pancreas, Breast, Monocytes, T cells

Animal Models for Ductal Carcinoma in Situ or affiliated genes

Sources:
37MGI, 28inGenious Targeting Laboratory
See all sources

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

37
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537610.6BNIP3, TIMP4, PGR, KRT14, ACTC1, BNIP3L
2MP:000200610.3TMEM158, ERBB2, KRT14, PGR, TFF1, CCND1

Publications for Ductal Carcinoma in Situ

Sources:
51PubMed
See all sources

Articles related to Ductal Carcinoma in Situ:

(show top 50)    (show all 240)
idTitleAuthorsYear
1
Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). (24346130)
2014
2
Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands. (24291376)
2014
3
The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ. (23851504)
2013
4
Synchronous ductal carcinoma in situ of the breast and within epithelial inclusions in an ipsilateral sentinel lymph node. (23089490)
2013
5
FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. (23712790)
2013
6
Detection of occult invasion in ductal carcinoma in situ of the breast with sentinel node metastasis. (23281914)
2013
7
Assessment of grating-based X-ray phase-contrast CT for differentiation of invasive ductal carcinoma and ductal carcinoma in situ in an experimental ex vivo set-up. (22932738)
2013
8
Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor. (23870857)
2013
9
Neuroendocrine ductal carcinoma in situ, comedo type, of the breast detected by screening mammography: a potentially pre-invasive counterpart of high grade neuroendocrine tumours. (22437750)
2012
10
Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature. (22606601)
2012
11
The evaluation of the immunoexpression of Her2A^neu oncoprotein in ductal carcinoma in situ in association with invasive ductal carcinoma of the breast. (23188444)
2012
12
Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop. (22488610)
2012
13
Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983-2007. (22340960)
2012
14
Multicentric and contralateral invasive tumors identified with pre-op MRI in patients newly diagnosed with ductal carcinoma in situ of the breast. (22804792)
2012
15
Ductal carcinoma in situ that involves sclerosing adenosis: high frequency of bilateral breast cancer occurrence. (23083502)
2012
16
Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer. (23216911)
2012
17
HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. (22361634)
2012
18
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. (22392043)
2012
19
Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy. (22445178)
2012
20
Intraoperative assessment of surgical margins during breast conserving surgery of ductal carcinoma in situ by use of radiofrequency spectroscopy. (21885281)
2011
21
Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive inA situ ductal carcinoma (IDCA +A DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade. (20143189)
2011
22
Ductal carcinoma in situ of the breast: influence of age on diagnostic, therapeutic, and prognostic features. Retrospective study of 812 patients. (21108045)
2011
23
Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ. (21741518)
2011
24
Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. (21042943)
2011
25
Use of preoperative MRI among older women with ductal carcinoma in situ and locally invasive breast cancer: Data Points # 13 (23115802)
2011
26
Her-2 positive ductal carcinoma in situ is an independent predictor of tumor recurrence. (21805692)
2011
27
Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast cancer: Data Points # 15 (23115801)
2011
28
Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. (21079099)
2010
29
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. (20663721)
2010
30
Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. (20848183)
2010
31
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. (20071685)
2010
32
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. (20427430)
2010
33
Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. (20469955)
2010
34
Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast. (19201736)
2009
35
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. (19473551)
2009
36
Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. (19675453)
2009
37
Comparative evaluation of the erbB2 and hormone receptor status of neighboring invasive and in situ components of ductal carcinomas of the breast. (20108215)
2009
38
High and intermediate grade ductal carcinoma in-situ of the breast: a comparison of pathologic features in core biopsies and excisions and an evaluation of core biopsy features that may predict a close or positive margin in the excision. (19691836)
2009
39
Aromatase expression in invasive and in situ ductal carcinoma present in the same breast]. (20191218)
2009
40
P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma. (19190693)
2007
41
The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern. (17618822)
2007
42
Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast. (17119686)
2006
43
An in situ carcinoma of the pancreas forming 2 invasive ductal carcinomas. (16025010)
2005
44
p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2. (15318938)
2004
45
Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation. (15528970)
2004
46
Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast. (12461058)
2002
47
Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. (11345835)
2001
48
Diagnosis of ductal carcinoma in situ (DCIS) and intraductal papilloma using fluorescence in situ hybridization (FISH) analysis. (11114860)
2000
49
Malignant myoepithelioma associated with in situ and invasive ductal carcinoma. Description of a case and review of the literature]. (9471611)
1997
50
High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. (8968105)
1996

Genetic Variations for Ductal Carcinoma in Situ

Expression for genes affiliated with Ductal Carcinoma in Situ

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Ductal Carcinoma in Situ

Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Pathways for genes affiliated with Ductal Carcinoma in Situ

Sources:
52QIAGEN, 38NCBI BioSystems Database, 54Reactome
See all sources

Compounds for genes affiliated with Ductal Carcinoma in Situ

Sources:
45Novoseek, 60Tocris Bioscience, 29IUPHAR, 11DrugBank, 24HMDB, 50PharmGKB, 2BitterDB
See all sources

Compounds related to Ductal Carcinoma in Situ according to GeneCards/GeneDecks:

(show all 35)
idCompoundScoreTop Affiliating Genes
1progesterone45 60 29 11 2415.1CCND1, TFF1, PIP, PGR, TAS2R64P, MMP26
2paraffin4511.1CCND1, TFF1, PIP, PGR, KRT5, KRT14
3steroid4511.1KLK10, CCND1, TFF1, PIP, PGR, TAS2R64P
4retinoic acid45 2412.0CCND1, S100A7, TFF1, PGR, MMP26, KRT5
5testosterone45 60 11 2414.0CCND1, TFF1, PIP, PGR, KRT5, ACTC1
6tamoxifen45 50 29 1114.0CCND1, TFF1, PIP, PGR, KRT14, ERBB2
7progestins4511.0KLK10, CCND1, TFF1, PIP, PGR
8retinoid4511.0CCND1, TFF1, PGR, KRT5, KRT14
94-hydroxytamoxifen4511.0CCND1, TFF1, PGR, ERBB2
10progestin4510.9CCND1, TFF1, PGR, ERBB2
11mucicarmine4510.9ACTC1, KRT14, PIP
12lapatinib45 50 1112.9ERBB2, PGR, CCND1
13estrogen4510.9S100A7
14resveratrol45 60 11 2413.9CCND1, TFF1, PGR, ERBB2
15toremifene45 1111.9TFF1, PGR, ERBB2
16fulvestrant45 50 29 1113.9ERBB2, PGR, TFF1
17letrozole45 50 60 1113.9ERBB2, PGR, TFF1
18genistein45 29 60 2 11 2415.9CCND1, TFF1, PGR, KRT5, ERBB2
19estradiol45 11 2412.9MMP26, PGR, PIP, TFF1, CCND1
20vegf4510.9BNIP3, CCND1, TFF1, PGR, ACTC1, ERBB2
21arzoxifene4510.8TFF1, CCND1
22dihydrotestosterone45 29 11 2413.8KLK10, PIP, PGR
23genistin 2 4511.8TFF1, CCND1
24trastuzumab45 50 1112.8ERBB2, PGR, CCND1
25norgestrel4510.8PGR, KLK10
26hematoxylin4510.8TFF1, KRT14, ACTC1
27paclitaxel45 50 1112.8ERBB2, PGR, CCND1, BNIP3
28gemcitabine45 50 1112.7BNIP3, CCND1, ERBB2
29geldanamycin45 50 60 1113.7CCND1, PGR, ERBB2
30calcium45 50 11 2413.6S100A7, TFF1, HCLS1, MMP26, KRT5, KRT14
312-methoxyethanol4510.6ACTC1, KRT14
32everolimus50 45 1112.6CCND1, ERBB2
33megestrol acetate4510.5ERBB2, PGR
34anastrozole45 1111.4PGR, ERBB2
35capecitabine45 50 1112.2ERBB2, PGR

GO Terms for genes affiliated with Ductal Carcinoma in Situ

Sources:
16Gene Ontology
See all sources

Cellular components related to Ductal Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1mitochondrial outer membraneGO:00574110.5PGR, BNIP3, BNIP3L

Biological processes related to Ductal Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1hemidesmosome assemblyGO:03158110.5KRT14, KRT5
2mitochondrial protein catabolic processGO:03569410.5BNIP3, BNIP3L
3epidermis developmentGO:00854410.4KRT14, KRT5, S100A7
4response to iron ionGO:01003910.2TFF1, CCND1

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:00551510.7ERBB2, BNIP3, CCND1, S100A7, TFF1, HCLS1

Products for genes affiliated with Ductal Carcinoma in Situ

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Ductal Carcinoma in Situ

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet